Goldman Sachs
AXN

Goldman Sachs’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Goldman Sachs’s Portfolio AXN Stock Details AXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,321
Closed -$24K – 7572
2015
Q1 		$24K Buy
+14,321
New +$13.4K ﹤0.01% 6879

Other funds holding AXN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Goldman Sachs's AXN Position: Q2 2015 in Review

Goldman Sachs sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q2 2015, closing a stake of 14,321 shares — an estimated $24K sold.

Goldman Sachs first reported a position in AXN in Q1 2015 and held it in 1 quarter. The position peaked at $24K in Q1 2015. 6 funds tracked by Wall St. Rank hold AXN as of Q2 2015.

  • Goldman Sachs reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q2 2015 after selling out during the quarter.
  • Goldman Sachs sold 14,321 Aoxing Pharmaceutical Company Inc. shares in Q2 2015, an estimated $24K.
  • Goldman Sachs first reported a position in Aoxing Pharmaceutical Company Inc. in Q1 2015 and held it in 1 quarter.
  • Goldman Sachs's Aoxing Pharmaceutical Company Inc. position peaked at $24K in Q1 2015.
  • 6 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q2 2015.

Based on Goldman Sachs's 13F filing for Q2 2015, filed 14 Aug 2015.